Perrigo Gets Final FDA OK, Plans Launch for Store Brand OTC Imodium Equivalent

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium^®Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer ‘own label’ brands and will provide consumers with a high-quality, value alternative to the national brand. Perrigo is finalizing plans to launch its wholly owned store brand loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, in the fourth quarter of 2018.

Imodium^® Multi-Symptom Relief is indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Retail sales for the last 12 months were approximately $62 million as measured by IRI.

https://www.marketscreener.com/PERRIGO-COMPANY-PLC-15809538/news/Perrigo-Announces-Final-FDA-Approval-and-Planned-Launch-for-the-Store-Brand-OTC-Equivalent-of-Imod-27226985/